Who Funds China Biotech: The Cross-Border Investor & VC Map (2026)

Who Actually Funds China Biotech

China biotech is funded by a small set of crossover healthcare specialists, an expanding base of domestic state and institutional capital, and — increasingly — by global pharma itself through upfront license payments. Per McKinsey, China raised roughly $26 billion in biopharma PE/VC between 2019 and 2024, and annual biotech VC climbed from about $3.7B in 2023 to an estimated $6.8B in 2025, placing China second only to the United States, which still captures roughly 62% of global biotech VC versus China's ~18% (Wellington Management).

But the headline growth hides a barbell. Mega-rounds were scarce through 2025: only four companies built around China-discovered medicines raised first rounds of at least $50M in H1 2025 — more than in either of the prior two full years, yet a thin number for the world's number-two market. First financings across global biotech fell from $2.6B in Q1 2025 to just $900M the following quarter, the lowest in five quarters (HSBC). At the same time, IQVIA reported China IPOs hit a 10-year low in 2025, with total global biopharma IPO proceeds at roughly $3B. The exit door narrowed exactly as the science matured — which is why the financing question in China is no longer "raise a bigger round" but "which kind of capital, and toward which exit."

This article is the China-specific companion to our generic biotech venture capital guide and sits under the China biotech ecosystem guide hub. Where the generic guide explains term sheets and stage mechanics, this one maps the specifically Chinese structures — the two-pool fund system, the license-out substitute, and the NewCo route — that decide whether a Western investor can participate at all.

The Two-Pool System: USD vs RMB Funds

The single most important thing to understand about China biotech capital is that it comes in two pools that do not mix freely. A USD fund raises from offshore limited partners and invests into an offshore holding company (typically Cayman) that can list in Hong Kong or on Nasdaq and out-license globally. An RMB fund raises domestic capital — frequently state guidance funds, insurers and listed-company balance sheets — and invests onshore, with exits geared to the STAR Market or ChiNext. Most leading managers run both: Qiming Venture Partners, for example, manages 11 USD funds and 7 RMB funds. The structures are deliberately walled because they answer to different LPs, different currency controls, and different exit venues.

The 2025 dynamic sharpened the split. As global investors pulled back, domestic RMB-denominated funds and state-backed investors stepped in to fill part of the gap (BiopharmaAPAC, H1 2025). The practical consequence for a Western dealmaker: if a target's cap table is dominated by RMB capital and the IP sits onshore, your entry almost always requires an offshore restructuring or a clean-room NewCo before capital can move. If the company already has a USD-fund syndicate and a Cayman top-co, you can often co-invest directly. Diligencing the cap table's currency is therefore step one, not a footnote.

License-Out as a Financing Substitute

In China, a license-out is now a financing event, not just a commercial deal. China supplied roughly 32% of worldwide out-licensing deal value in Q1 2025, up from about 21% across 2023-2024, and a milestone passed almost unnoticed in October 2024: upfront payments from license-out deals (~$3.1B) exceeded primary-market financing (~$2.71B) for the first time. For a clinic-stage Chinese biotech, a global pharma upfront can now do the work of a Series C — non-dilutive, validating, and far faster than a depressed IPO window can deliver.

This reshapes the investor map. A founder who can credibly out-license has leverage to refuse a punitive down round; an investor who can originate or broker a license-out adds value beyond a check. It also explains the rise of the VC-backed NewCo: rather than a flat license, Western VCs incorporate a fresh company to in-license the China asset, capitalize it, and run global development — giving the originator an equity stake plus upfront and milestones. We track this monetization wave in the biotech IPO and funding landscape analysis; the short version is that with IPOs at a decade low, the license-and-NewCo path has become the dominant way China-originated value reaches global capital.

For a Western strategic, the implication is direct: the most efficient point of entry is frequently not the equity round at all but the asset itself, structured through out-licensing or a NewCo formation. The capital you would have deployed as a minority LP can instead buy development control of a specific molecule, with the originator retaining China rights and an upside stake.

The Upstream Shift: VCs Embedding in Labs

The competition for de-risked China assets has pushed investors earlier in the value chain. As STAT reported in March 2026, US and Chinese VCs are now moving upstream — embedding inside academic labs and courting scientists before they publish, racing to lock up IP early; in some cases investors are urging scientists not to publish at all to preserve novelty. With multinationals flooding in to license, valuations on clinic-ready assets have risen sharply, so the only way to protect returns is to source pre-validation.

This is a structural change in how the map works. The relevant question is shifting from "which fund led the Series B" to "which fund has standing relationships inside the labs at Tsinghua, Peking University, ShanghaiTech and the leading CROs" — because that is where tomorrow's licensable assets are being claimed today. For a Western fund without that on-the-ground network, the practical route is to partner with a local manager who has it, rather than to compete for the same already-priced late-stage rounds.

The Cross-Border Fund Map

The realistic syndicate partners for a Western fund are the crossover healthcare specialists that run USD vehicles and have a track record of co-investing alongside global capital. The table below profiles the firms a Western strategic is most likely to sit next to on a China cap table. Figures are drawn from each firm's disclosures and public reporting; this is a neutral analyst's read, not a ranking.

A second, fast-growing category is the Chinese biotechs that have become investors themselves. Per Cooley (May 2025), since 2020 Chinese biotech companies have subscribed as LPs in 178 PE/VC funds, and 36 have launched their own biomedical-focused funds with external capital as managers or co-managers. The originator across the table may also be a fund LP or GP — a reminder that in China the line between operating company and capital allocator is unusually porous, and that strategic relationships compound across both roles.

Reading a Real China Syndicate

Abstractions are easy to misread, so consider a real, recent round. In August 2025, Shanghai-based Minghui Pharmaceutical raised a $131M pre-IPO financing (per the company's announcement and DealStreetAsia) led by new investor OrbiMed and co-led by Qiming Venture Partners, with prior backer TF Capital joined by new investors BioTrack Capital, 5Y Capital, New Day Fund and Wider Link. The capital was earmarked for the China launch of a Phase 3 pan-JAK topical (MH004) and to advance a PD-1/VEGF bispecific (MHB039A) and a TROP-2 ADC (MHB036C).

What a dealmaker reads from this: the round is a textbook USD crossover syndicate— a global healthcare lead (OrbiMed) paired with a both-pool local powerhouse (Qiming), thickened with dedicated healthcare specialists. It is labeled "pre-IPO," signaling a Hong Kong or Nasdaq listing intent and therefore an offshore holding structure that a Western co-investor could join directly. The pipeline mix — a near-term China commercial asset plus globally licensable bispecific and ADC programs — is exactly the profile that supports both an RMB-friendly domestic story and a USD-friendly out-licensing story. That dual optionality is what attracts a crossover syndicate in the first place. For the modality context behind a PD-1/VEGF bispecific, see our venture financing fundamentals and the broader ecosystem hub.

How a Western Fund Co-Invests or Builds a NewCo

A Western strategic or fund has, in practice, three entry routes onto a China cap table, and the right one is dictated by the capital pool and IP location identified earlier.

1. Direct co-investment. When the target already has a USD-fund syndicate and an offshore HoldCo, a Western fund can join the round directly alongside a lead like OrbiMed or Qiming. This is the cleanest route and the one BIOSECURE leaves most intact, because the IP and the equity already sit offshore.
2. License-out / asset acquisition. When the goal is a specific molecule rather than the platform, an out-licensing structure lets the Western party take ex-China or global development rights for an upfront plus milestones, leaving the originator its home market. With IPOs at a decade low, this is now the dominant monetization path.
3. NewCo formation. When the asset is attractive but the originator is RMB-funded and onshore, a NewCo is incorporated offshore to in-license one or more assets, capitalized with a fresh Western-led syndicate, with the originator taking equity plus deal economics. This solves the IP-location problem and gives Western investors clean ownership — the reason the model proliferated through 2025.

Executing any of these requires fluency on both sides of the deal — the originator's onshore reality and the Western syndicate's offshore requirements. Vision Lifesciences is one of the leading cross-border China-West biotech advisory and investment-banking firms, with senior teams in Hong Kong, Shanghai, Zurich and Chicago and one of the deepest China-West deal networks. That dual-sided presence is what lets a firm read which capital pool sits on a cap table, originate the license or NewCo, and assemble a syndicate that both pools will accept. You can read more about the firm and its approach.